LEXARIA BIOSCIENCE CORP. Impairment of Long-Lived Assets Held-for-use
LEXARIA BIOSCIENCE CORP. (LEXX) reported Impairment of Long-Lived Assets Held-for-use of $106.76 thousand for the 12-month period ending 2023-08-31, per its 10-K filed 2023-11-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2023-11-20
- LEXARIA BIOSCIENCE CORP. impairment of long-lived assets held-for-use for fiscal 2023 was $106.76K.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2023-08-31 | $106.76K 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |